Page 7 - Nasdaq Nrix News Today : Breaking News, Live Updates & Top Stories | Vimarsana

SAN FRANCISCO, Sept. 14, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company developing targeted...

Nurix Therapeutics (NASDAQ: NRIX) recently received a number of ratings updates from brokerages and research firms: 4/18/2022 – Nurix Therapeutics had its price target lowered by analysts at Royal Bank of Canada from $42.00 to $39.00. They now have an “outperform” rating on the stock. 4/14/2022 – Nurix Therapeutics had its price target lowered by […]

Nurix Therapeutics (NASDAQ:NRIX – Get Rating) had its target price reduced by stock analysts at Wells Fargo & Company from $28.00 to $25.00 in a research note issued on Monday, Marketbeat.com reports. The firm presently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price points to a potential upside of […]

Brokerages expect Nurix Therapeutics, Inc. (NASDAQ:NRIX – Get Rating) to report sales of $9.59 million for the current fiscal quarter, Zacks reports. Four analysts have made estimates for Nurix Therapeutics’ earnings, with estimates ranging from $8.00 million to $11.54 million. Nurix Therapeutics posted sales of $7.09 million during the same quarter last year, which indicates […]

Nurix Therapeutics (NASDAQ:NRIX – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Saturday, Zacks.com reports. According to Zacks, “Nurix Therapeutics Inc.is a biopharmaceutical company. It focuses on the discovery, development and commercialization of small molecule therapies for the treatment of cancer and […]